146 related articles for article (PubMed ID: 19475723)
1. Pilot study to evaluate the efficacy and tolerability of levetiracetam (Keppra) in treatment of patients with trigeminal neuralgia.
Jorns TP; Johnston A; Zakrzewska JM
Eur J Neurol; 2009 Jun; 16(6):740-4. PubMed ID: 19475723
[TBL] [Abstract][Full Text] [Related]
2. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
Abou-Khalil B; Hemdal P; Privitera MD
Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
[TBL] [Abstract][Full Text] [Related]
3. An observational trial to investigate the efficacy and tolerability of levetiracetam in trigeminal neuralgia.
Mitsikostas DD; Pantes GV; Avramidis TG; Karageorgiou KE; Gatzonis SD; Stathis PG; Fili VA; Siatouni AD; Vikelis M
Headache; 2010 Sep; 50(8):1371-7. PubMed ID: 21044281
[TBL] [Abstract][Full Text] [Related]
4. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial.
Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM;
Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial.
Glauser TA; Pellock JM; Bebin EM; Fountain NB; Ritter FJ; Jensen CM; Shields WD
Epilepsia; 2002 May; 43(5):518-24. PubMed ID: 12027913
[TBL] [Abstract][Full Text] [Related]
6. Intravenous levetiracetam in clinical practice--Results from an independent registry.
Lang N; Esser W; Evers S; Kellinghaus C; Nguento A; Schlegel U; Gaida B; Gburek-Augustat J; Altenmüller DM; Burghaus L; Hoffmann F; Fiedler B; Bast T; Rehfeld T; Happe S; Seitz RJ; Boor R; Stephani U
Seizure; 2015 Jul; 29():109-13. PubMed ID: 26076852
[TBL] [Abstract][Full Text] [Related]
7. Levetiracetam in patients with central neuropathic post-stroke pain--a randomized, double-blind, placebo-controlled trial.
Jungehulsing GJ; Israel H; Safar N; Taskin B; Nolte CH; Brunecker P; Wernecke KD; Villringer A
Eur J Neurol; 2013 Feb; 20(2):331-7. PubMed ID: 22925226
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of levetiracetam as adjunctive treatment for refractory canine epilepsy: a randomized, placebo-controlled, crossover trial.
Muñana KR; Thomas WB; Inzana KD; Nettifee-Osborne JA; McLucas KJ; Olby NJ; Mariani CJ; Early PJ
J Vet Intern Med; 2012; 26(2):341-8. PubMed ID: 22295869
[TBL] [Abstract][Full Text] [Related]
9. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus.
Frucht SJ; Louis ED; Chuang C; Fahn S
Neurology; 2001 Sep; 57(6):1112-4. PubMed ID: 11571347
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group.
Ben-Menachem E; Falter U
Epilepsia; 2000 Oct; 41(10):1276-83. PubMed ID: 11051122
[TBL] [Abstract][Full Text] [Related]
11. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures.
Wu XY; Hong Z; Wu X; Wu LW; Wang XF; Zhou D; Zhao ZX; Lv CZ
Epilepsia; 2009 Mar; 50(3):398-405. PubMed ID: 18657175
[TBL] [Abstract][Full Text] [Related]
12. Double-masked, placebo-controlled study of intravenous levetiracetam for the treatment of status epilepticus and acute repetitive seizures in dogs.
Hardy BT; Patterson EE; Cloyd JM; Hardy RM; Leppik IE
J Vet Intern Med; 2012; 26(2):334-40. PubMed ID: 22295898
[TBL] [Abstract][Full Text] [Related]
13. An open-label pilot study of levetiracetam for essential tremor.
Ondo WG; Jimenez JE; Vuong KD; Jankovic J
Clin Neuropharmacol; 2004; 27(6):274-7. PubMed ID: 15613931
[TBL] [Abstract][Full Text] [Related]
14. Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy.
Boon P; Chauvel P; Pohlmann-Eden B; Otoul C; Wroe S
Epilepsy Res; 2002 Jan; 48(1-2):77-89. PubMed ID: 11823112
[TBL] [Abstract][Full Text] [Related]
15. Levetiracetam extended release and levetiracetam immediate release as adjunctive treatment for partial-onset seizures: an indirect comparison of treatment-emergent adverse events using meta-analytic techniques.
Richy FF; Banerjee S; Brabant Y; Helmers S
Epilepsy Behav; 2009 Oct; 16(2):240-5. PubMed ID: 19699156
[TBL] [Abstract][Full Text] [Related]
16. Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study.
Rossi S; Mataluni G; Codecà C; Fiore S; Buttari F; Musella A; Castelli M; Bernardi G; Centonze D
Eur J Neurol; 2009 Mar; 16(3):360-6. PubMed ID: 19364364
[TBL] [Abstract][Full Text] [Related]
17. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease.
Zesiewicz TA; Sullivan KL; Hauser RA; Sanchez-Ramos J
Mov Disord; 2006 Nov; 21(11):1998-2001. PubMed ID: 16941461
[TBL] [Abstract][Full Text] [Related]
18. Levetiracetam in social phobia: a placebo controlled pilot study.
Zhang W; Connor KM; Davidson JR
J Psychopharmacol; 2005 Sep; 19(5):551-3. PubMed ID: 16166192
[TBL] [Abstract][Full Text] [Related]
19. Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study.
Delanty N; Jones J; Tonner F
Epilepsia; 2012 Jan; 53(1):111-9. PubMed ID: 22050371
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy.
Grant R; Shorvon SD
Epilepsy Res; 2000 Dec; 42(2-3):89-95. PubMed ID: 11074181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
